Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638493 | 1.00 | FOLH1 (0.41) | FOLH1GNPATGGT1C3AR1SIRT5 | |
| Hydrochloric Acid SCHEMBL8377718 | 0.98 | FOLH1 (0.40) | FOLH1GNPATGGT1C3AR1SIRT5 | |
| Hydrochloric Acid SCHEMBL16892661 | 0.98 | FOLH1 (0.40) | FOLH1GNPATGGT1C3AR1SIRT5 | |
| Hydrochloric Acid SCHEMBL8377717 | 0.98 | FOLH1 (0.40) | FOLH1GNPATGGT1C3AR1SIRT5 | |
| SCHEMBL19506115 | 0.90 | PRMT1 (0.45) | FOLH1SIRT5NOD1NPY1RNPY2R | |
| SCHEMBL144726 | 0.89 | GGT1 (0.40) | FOLH1GGT1C3AR1NOD1ALOX15 | |
| SCHEMBL1149706 | 0.87 | NOD1 (0.43) | FOLH1GGT1C3AR1NOD1ALOX15 | |
| SCHEMBL933117 | 0.86 | C3AR1 (0.38) | FOLH1GNPATGGT1C3AR1NOD1 | |
| SCHEMBL13060031 | 0.86 | GGT1 (0.38) | FOLH1GGT1C3AR1NOD1ALOX15 | |
| SCHEMBL611883 | 0.86 | GGT1 (0.53) | FOLH1GGT1C3AR1NOD1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114624362-A | Kit for detecting advanced glycosylation end products in serum and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-06-14 | — | — | CN | claimed |
| EP-1218486-A4 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | UNIV JOHNS HOPKINS (US) | 2002-11-04 | — | — | EP | claimed |
| EP-1218486-A1 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | The Johns-Hopkins University (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001019959-A1 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2001-03-22 | — | — | WO | claimed |
| CN-116497074-A | Synthesis method of lactam compound | 中国科学院天津工业生物技术研究所 | 2023-07-28 | — | — | CN | disclosed |
| CN-114624362-A | Kit for detecting advanced glycosylation end products in serum and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-06-14 | — | — | CN | disclosed |
| WO-2022018258-A1 | IMPROVED PROCESS FOR PRODUCTION OF CLAVULANIC ACID | SANDOZ AG (CH) | 2022-01-27 | — | — | WO | disclosed |
| US-10662394-B2 | Aqueous extraction process for the recovery of mucilage and demulsification | DREI LILIEN PVG GMBH & CO. KG (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190153353-A1 | AQUEOUS EXTRACTION PROCESS FOR THE RECOVERY OF MUCILAGE AND DEMULSIFICATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2019-05-23 | — | — | US | disclosed |
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | NANOSCIENCE FOR LIFE GMBH & COKG (DE) | 2019-03-26 | — | — | US | disclosed |
| US-9994464-B2 | Method and devices for de-emulsifying and complexing organic compounds in emulsions | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9932540-B2 | Method for refining lipid phases, and use | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-04-03 | — | — | US | disclosed |
| WO-2011160857-A2 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2011-12-29 | — | — | WO | disclosed |
| EP-2399885-A1 | Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification | Dietz, Ulrich (DE) | 2011-12-28 | — | — | EP | disclosed |
| EP-1218486-A4 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | UNIV JOHNS HOPKINS (US) | 2002-11-04 | — | — | EP | disclosed |
| EP-1218486-A1 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | The Johns-Hopkins University (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001019959-A1 | IMPROVEMENT OF CLAVULANIC ACID PRODUCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0673432-B1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1999-03-24 | — | — | EP | disclosed |
| EP-0673432-A1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994012654-A1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | AGL, LIPA, MGLL | FOLH1 1223/4885GNPAT 113/4885GGT1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.